Genetic and biochemical analysis of the reserve carbohydrate metabolism in Candida albicans and Candida rugosa

2018 ◽  
Vol 10 (2) ◽  
pp. 61-77
Author(s):  
Hulya Karaca Gencer ◽  
Merih Kivanc ◽  
Sezai Turkel
2016 ◽  
Vol 6 (5) ◽  
pp. 1327-1343 ◽  
Author(s):  
Fernanda Zanolli Freitas ◽  
Stela Virgilio ◽  
Fernanda Barbosa Cupertino ◽  
David John Kowbel ◽  
Mariana Fioramonte ◽  
...  

2004 ◽  
Vol 72 (5) ◽  
pp. 2513-2520 ◽  
Author(s):  
Ningfeng Tang ◽  
Liming Liu ◽  
Kefei Kang ◽  
Pranab K. Mukherjee ◽  
Masakazu Takahara ◽  
...  

ABSTRACT Our previous data demonstrated that live Candida albicans inhibits interleukin-12 (IL-12) production by human monocytes. Here we explored whether C. albicans inhibits IL-12 via a released factor and whether the inhibition is mediated via mitogen-activated protein kinase (MAPK) regulation. Supernatant fluids were obtained from cultured C. albicans (SC5314) as well as cultured Saccharomyces cerevisiae after 20 h of incubation. At 2 h postincubation of monocytes with heat-killed C. albicans (HKCA) (2:1) to stimulate IL-12, concentrated fungal supernatant fluids were added and incubated for an additional 20 h. The present data show that, unlike supernatant fluids obtained from S. cerevisiae, the C. albicans supernatant fluids significantly suppressed IL-12 production induced by HKCA. This suggested that the inhibition is Candida specific. A preliminary biochemical analysis revealed that this secretory IL-12 inhibitory factor is glycoprotein in nature. The inhibitory activity had no effect on the phagocytosis of yeasts. Supernatant fluids from C. albicans markedly induced the phosphorylation of ERK44/42 MAPK, but not p38 and SAPK, 1 min after they were added to monocytes. To test if the induction of ERK44/42 MAPK was central to the IL-12 inhibition, we used gamma interferon (IFN-γ) (1 ng/ml) plus lipopolysaccharide (LPS) (100 ng/ml) to stimulate IL-12 production by monocytes. The inhibition of ERK MAPK by the specific inhibitor PD 98059 significantly reduced phospho-ERK44/42 MAPK levels induced by C. albicans supernatant fluids in the IFN-γ-plus-LPS-driven monocytes. Concomitantly, PD 98059 reversed the IL-12 inhibitory activity of the C. albicans supernatant (P < 0.01). These data indicate that C. albicans can inhibit IL-12 production by secreting an ERK44/42 MAPK-stimulating factor and thus can attenuate effective immune responses.


2020 ◽  
Vol 20 (1) ◽  
pp. 127-138
Author(s):  
Safia Gacemi ◽  
Khedidja Benarous ◽  
Santiago Imperial ◽  
Mohamed Yousfi

Background and Objective: The present paper aims to study the inhibition of Candida albicans growth as candidiasis treatment, using seeds of Lepidium sativum as source. Methods: In vitro assays were carried out on the antifungal activity of three kinds of extracts from L. sativum seeds against four strains of C. albicans, then testing the same phytochemicals on the inhibition of Lipase (LCR). A new in silico study was achieved using molecular docking, with Autodock vina program, to find binding affinity of two important and major lepidine alkaloids (lepidine E and B) towards the four enzymes secreted by C. albicans as target drugs, responsible of vitality and virulence of this yeast cells: Lipase, Serine/threonine phosphatase, Phosphomannose isomerase and Sterol 14-alpha demethylase (CYP51). Results: The results of the microdillution assay show that the hexanic and alkaloidal extracts have an antifungal activity with MICs: 2.25 mg/ml and 4.5mg/ml, respectively. However, Candida rugosa lipase assay gives a remarkable IC50 values for the hexanic extract (1.42± 0.04 mg/ml) followed by 1.7± 0.1 and 2.29 ± 0.09 mg/ml of ethyl acetate and alkaloidal extracts respectively. The molecular docking confirms a significant correlation between C. albicans growth and inhibition of crucial enzymes involved in the invasion mechanism and cellular metabolisms, for the first time there were an interesting and new positive results on binding modes of lepidine E and B on the four studied enzymes. Conclusion: Through this work, we propose Lepidine B & E as potent antifungal drugs.


2009 ◽  
Vol 5 (10) ◽  
pp. e1000612 ◽  
Author(s):  
Christopher Askew ◽  
Adnane Sellam ◽  
Elias Epp ◽  
Hervé Hogues ◽  
Alaka Mullick ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document